Goldman Sachs Downgrades Incyte to Neutral, Announces $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter downgraded Incyte (NASDAQ:INCY) from Buy to Neutral and set a price target of $65.

November 21, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs downgraded Incyte from Buy to Neutral and set a price target of $65, potentially impacting investor sentiment and the stock's market performance.
Downgrades by major analysts like Goldman Sachs can lead to a negative short-term reaction in the stock market as they may indicate a less favorable outlook for the company's future performance. The setting of a price target provides a specific expectation for the stock's potential value, which can influence investor decisions and stock price movements.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100